Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical ...

The new test has demonstrated an initial 94% sensitivity rate in tumour detection and the test is delivered in under 20 ...

Overall, PSMA-PET/CT detected distant metastasis in 84 of 182 cases (46%) that were negative by other types of imaging, ...

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

Prostate cancer screening breakthrough could cut time of test to twenty minutes - One in eight men will be diagnosed with ...

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

A novel polygenic risk score (PRS) may be useful for identifying men on active surveillance (AS) for prostate cancer who are ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Researchers say they have been encouraged by trials of a new process to detect prostate cancer in men. It is hoped that the ...

Radical prostatectomy is a standard treatment for prostate cancer, yet about 30% of patients experience rising biochemical markers within a decade post-surgery. Pelvic lymph node sampling during ...